NCT01421576

Brief Summary

A randomized, open-label, single-dose, crossover clinical trial to evaluate the food effect on the pharmacokinetics of DP-R202 tablet after oral administration in healthy male volunteers.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at P25-P50 for phase_1 healthy

Timeline
Completed

Started Jul 2011

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2011

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2011

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

August 9, 2011

Completed
14 days until next milestone

First Posted

Study publicly available on registry

August 23, 2011

Completed
Last Updated

August 23, 2011

Status Verified

August 1, 2011

Enrollment Period

Same day

First QC Date

August 9, 2011

Last Update Submit

August 22, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • Composite of Pharmacokinetics(Cmax, AUClast)

    24h

Study Arms (2)

High fat meal

ACTIVE COMPARATOR
Dietary Supplement: High fat meal

DP-R202

EXPERIMENTAL

under fed condition

Dietary Supplement: High fat meal

Interventions

High fat mealDIETARY_SUPPLEMENT

offer high fat-meal in the morning before drug intake.

Also known as: Other Names:, DP-R202 : DP11002-3
DP-R202High fat meal

Eligibility Criteria

Age20 Years - 55 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • to 55 years of healthy volunteers

You may not qualify if:

  • Hypersensitivity Reaction about Sarpogrelate HCL or other antiplatelets

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Samsung Medical Center

Seoul, Gangnam, 135-710, South Korea

Location

Study Officials

  • Jae Wook Ko, M.D., Ph.D

    Samsung Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 9, 2011

First Posted

August 23, 2011

Study Start

July 1, 2011

Primary Completion

July 1, 2011

Study Completion

July 1, 2011

Last Updated

August 23, 2011

Record last verified: 2011-08

Locations